EVIA Life Sciences Inc. — SEC Form D Filing
EVIA Life Sciences Inc. filed an SEC Form D on November 2, 2026, reporting $700K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 2, 2026
- Amount reported
- $700K
- Round stage
- Seed stage based on raising $700,002 to scale early commercial manufacturing of its novel formulation portfolio.
- Industry
- Biotechnology
- Website
- https://evialifesciences.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Traditional cell cryopreservation relies on toxic dimethyl sulfoxide, which compromises post-thaw cell viability and presents health risks for cell therapy patients.
Solution
EVIA Life Sciences produces non-DMSO cryopreservation solutions utilizing natural organic compounds to maintain cell viability and safety for cell therapy and reproductive medicine.
Why now
The rapid clinical adoption of advanced cell therapies requires non-toxic biopreservation media to eliminate toxic washing steps and meet stricter regulatory standards.
Source: SEC EDGAR Form D filing